BioNTech SE (BNTX) Cash from Investing Activities (2018 - 2025)
BioNTech SE (BNTX) posted Cash from Investing Activities of -$3.2 billion for Q4 2025, down 193.3% sequentially from -$1.1 billion in Q3 2025, and down 589.38% YoY from $648.3 million in Q4 2024.
BioNTech SE (BNTX) Cash from Investing Activities (2018 - 2025) Analysis & Trends
BioNTech SE has reported Cash from Investing Activities for 8 years, with the latest figure at -$3.2 billion in Q4 2025.
- Quarterly Cash from Investing Activities fell 589.38% year-over-year to -$3.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.0 billion (down 32.79% YoY) and the FY2025 annual result came in at -$2.8 billion, down 25.4% from the prior year.
- Cash from Investing Activities declined to -$3.2 billion in Q4 2025 per BNTX's latest filing, from -$1.1 billion in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $1.3 billion in Q1 2025 and troughed at -$3.2 billion in Q4 2025.
- A 5-year average of -$588.0 million and a median of -$83.8 million in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2023: Cash from Investing Activities surged 96043426.27% in 2021, then slumped 2883.12% in 2023.
- Over 5 years, Cash from Investing Activities stood at $114.3 million in 2021, then jumped by 43.73% to $164.3 million in 2022, then plunged by 1865.35% to -$2.9 billion in 2023, then soared by 122.36% to $648.3 million in 2024, then tumbled by 589.38% to -$3.2 billion in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$3.2 billion, -$1.1 billion, and -$72.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -3.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.17 Bn |
| Dec 31, 2025 | -3.17 Bn |
| Sep 30, 2025 | -1.08 Bn |
| Sep 30, 2025 | -1.08 Bn |
| Jun 30, 2025 | -72.90 Mn |
| Jun 30, 2025 | -72.90 Mn |
| Mar 31, 2025 | 1.31 Bn |
| Mar 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | 648.32 Mn |
| Dec 31, 2024 | 648.32 Mn |
| Sep 30, 2024 | -156.06 Mn |
| Sep 30, 2024 | -156.06 Mn |
| Jun 30, 2024 | -259.96 Mn |
| Jun 30, 2024 | -259.96 Mn |
| Mar 31, 2024 | -2.50 Bn |
| Mar 31, 2024 | -2.50 Bn |
| Dec 31, 2023 | -2.90 Bn |
| Dec 31, 2023 | -2.90 Bn |
| Sep 30, 2023 | -1.34 Bn |
| Sep 30, 2023 | -1.34 Bn |